Overcoming PARP Inhibitor and Platinum Resistance with WEE1 Inhibitors in Ovarian Cancer
Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment of high-grade epithelial ovarian cancer (EOC), with demonstrated efficacy in the recurrent as well as newly diagnosed disease. However, women with EOC inevitably acquire resistance to both platinum chemotherapy and PARPi....
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.09.047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Poly (ADP-ribose) polymerase inhibitors (PARPi) have transformed the treatment of high-grade epithelial ovarian cancer (EOC), with demonstrated efficacy in the recurrent as well as newly diagnosed disease. However, women with EOC inevitably acquire resistance to both platinum chemotherapy and PARPi. Combining PARPi with agents targeting other DNA damage response (DDR) pathways to promote synthetic lethality is a rational therapeutic approach. Recent studies show that combination of PARPi and WEE1 inhibitors is feasible and might be an effective strategy for patients with platinum- and PARPi-resistant EOC. This article provides an overview of the latest preclinical and clinical trials evaluating WEE1 inhibitors in monotherapy or in combination with PARPi in advanced EOC. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |